caa a22 4500 606245456 CHVBK 20210128101335.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s12262-015-1305-9 doi (NATIONALLICENCE)springer-10.1007/s12262-015-1305-9 The Effect of Helicobacter pylori on Gastric Cancer Treated with Adjuvant Chemotherapy After Curative Resection [Elektronische Daten] [Sevim Turanli, Nazan Bozdogan, Hakan Mersin, Ugur Berberoglu] Helicobacter pylori has been associated with diverse pathologies of varying severity. We investigated the H. pylori infection status and its association with the pathologic features and clinical outcomes in stage III gastric cancer patients treated with adjuvant therapy after curative resection. Between 2004 and 2009, the records of 76 consecutive patients were retrospectively reviewed. H. pylori infection was confirmed by examination of pathological specimen. The relationship between H. pylori and the clinicopathological features was analyzed by Fisher exact test, Student's t test, and Kaplan-Meier method. Of the 76 patients, 16 patients (21.1%) were confirmed for H. pylori infection. The median age was 59years. Twenty-three patients received chemotherapy and remainder received chemoradiotherapy. H. pylori status did not correlate with the clinicopathologic features. It was greater in non-neoplastic tissue than the tumor tissue (21.1 vs 7.9%). Median follow-up was 21months. During this period, 88.2% patients had experienced tumor recurrence, and 85.5% patients had died. Recurrence was observed in 87.5% patients and in 88.3% patients in H. pylori-positive and H. pylori-negative patients, respectively (P = 0.92). Disease-free survival was 28.4 ± 7.9months and overall survival was 31.5 ± 7.4months in H. pylori-positive patients compared with 28.3 ± 3.7 and 33.2 ± 3.4months, respectively, in H. pylori-negative patients. H. pylori infection status did not have effect on the overall or disease-free survival (p = 0.85 and P = 0.86), respectively. H. pylori status might not be useful as a prognostic and predictive factor for clinical outcomes. Association of Surgeons of India, 2015 Helicobacter pylori nationallicence Gastric carcinoma nationallicence Prognosis nationallicence Survival nationallicence Turanli Sevim Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut Bozdogan Nazan Department of Pathology, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut Mersin Hakan Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut Berberoglu Ugur Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut Indian Journal of Surgery Springer India 77/6(2015-12-01), 489-494 0972-2068 77:6<489 2015 77 12262 https://doi.org/10.1007/s12262-015-1305-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s12262-015-1305-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Turanli Sevim Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut NATIONALLICENCE 700 1- Bozdogan Nazan Department of Pathology, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut NATIONALLICENCE 700 1- Mersin Hakan Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut NATIONALLICENCE 700 1- Berberoglu Ugur Department of General Surgery, Ankara Oncology Education and Research Hospital, Demetevler, 06200, Ankara, Turkey aut NATIONALLICENCE 773 0- Indian Journal of Surgery Springer India 77/6(2015-12-01), 489-494 0972-2068 77:6<489 2015 77 12262